Jefferies Group Comments on Radius Health, Inc.’s Q3 2017 Earnings (RDUS)
Radius Health, Inc. (NASDAQ:RDUS) – Investment analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Radius Health in a research report issued to clients and investors on Monday. Jefferies Group analyst E. Yang expects that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter. Jefferies Group currently has a “Hold” rating and a $34.00 price target on the stock. Jefferies Group also issued estimates for Radius Health’s Q4 2017 earnings at ($1.20) EPS, FY2017 earnings at ($5.20) EPS, FY2019 earnings at ($3.57) EPS, FY2020 earnings at ($2.15) EPS and FY2021 earnings at $1.03 EPS.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by $0.14. During the same quarter last year, the business earned ($0.94) earnings per share. WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/26/jefferies-group-comments-on-radius-health-inc-s-q3-2017-earnings-rdus.html.
Several other brokerages also recently weighed in on RDUS. BidaskClub raised Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $55.67.
Radius Health (RDUS) opened at 42.94 on Wednesday. The firm’s market cap is $1.86 billion. The stock has a 50 day moving average price of $43.50 and a 200-day moving average price of $40.65. Radius Health has a 12-month low of $31.58 and a 12-month high of $59.88.
In other news, major shareholder Growth N. V. Biotech purchased 43,400 shares of the stock in a transaction dated Monday, May 8th. The shares were bought at an average cost of $35.57 per share, for a total transaction of $1,543,738.00. Following the transaction, the insider now owns 4,785,999 shares in the company, valued at $170,237,984.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech purchased 150,000 shares of the stock in a transaction dated Monday, May 1st. The shares were purchased at an average price of $35.39 per share, for a total transaction of $5,308,500.00. Following the completion of the transaction, the insider now owns 4,690,399 shares in the company, valued at approximately $165,993,220.61. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 498,400 shares of company stock worth $17,411,288. 15.00% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of RDUS. Ameritas Investment Partners Inc. purchased a new position in shares of Radius Health during the first quarter valued at about $105,000. Envestnet Asset Management Inc. boosted its position in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Radius Health during the fourth quarter valued at about $197,000. Karp Capital Management Corp purchased a new position in shares of Radius Health during the first quarter valued at about $217,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Radius Health during the first quarter valued at about $228,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.